Multiple primary cancers in patients with osteosarcoma - Influence of anticancer drugs and genetic factors

被引:10
作者
Yonemoto, T [1 ]
Tatezaki, S [1 ]
Ishii, T [1 ]
Hagiwara, Y [1 ]
Inoue, M [1 ]
机构
[1] Natl Chiba Higashi Hosp, Div Orthopaed Surg, Chuo Ku, Chiba 2608717, Japan
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2004年 / 27卷 / 03期
关键词
osteosarcoma; multiple primary cancers; chemotherapy; germ-line p53 gene mutation;
D O I
10.1097/01.COC.0000054534.43117.76
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
One hundred thirty-five patients younger than 30 years with osteosarcoma were treated at the Chiba Cancer Center between 1976 and 1999. They included six patients with second cancer after cure of osteosarcoma (group A) and three patients with osteosarcoma as second cancer after cure of childhood cancers (group B). Third cancer occurred in one patient of group A. The clinical features of these nine patients were studied. The diagnoses of second cancer in group A consisted of two acute myelogenous leukemias, two breast carcinomas, one malignant phyllodes tumor of breast, and one ovarian carcinoma. The third cancer was uterine leiomyosarcoma. Second cancer occurred an average of 7.2 years after occurrence of osteosarcoma. The diagnoses of first cancer in group B consisted of one adrenocortical carcinoma, one malignant teratoma of sacrum, and one ovarian carcinoma (yolk sac tumor). Osteosarcoma occurred on average 12.7 years after occurrence of first cancer. Two patients had germ-line p53 gene mutation. Anticancer drugs and genetic factors are presumed to be concerned with occurrence of second cancer. The frequency of multiple primary cancers in patients with osteosarcoma is by no means low. Strict follow-up is thus needed over a long period.
引用
收藏
页码:220 / 224
页数:5
相关论文
共 34 条
[11]   2ND MALIGNANT NEOPLASMS IN CHILDREN TREATED FOR RHABDOMYOSARCOMA [J].
HEYN, R ;
HAEBERLEN, V ;
NEWTON, WA ;
RAGAB, AH ;
RANEY, RB ;
TEFFT, M ;
WHARAM, M ;
ENSIGN, LG ;
MAURER, HM .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (02) :262-270
[12]   Osteosarcoma as a second malignancy after treatment for neuroblastoma [J].
Iwata, A ;
Hirota, T ;
Konno, K ;
Fujimoto, T ;
Sumida, S ;
Sato, K ;
Hara, K .
PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2001, 18 (07) :465-469
[13]   Mechanism-based chemopreventive strategies against etoposide-induced acute myeloid leukemia: Free radical/antioxidant approach [J].
Kagan, VE ;
Yalowich, JC ;
Borisenko, GG ;
Tyurina, YY ;
Tyurin, VA ;
Thampatty, P ;
Fabisiak, JP .
MOLECULAR PHARMACOLOGY, 1999, 56 (03) :494-506
[14]  
Le Vu B, 1998, INT J CANCER, V77, P370, DOI 10.1002/(SICI)1097-0215(19980729)77:3<370::AID-IJC11>3.0.CO
[15]  
2-C
[16]  
LI FP, 1969, J NATL CANCER I, V43, P1365
[17]   Brain tumors as second malignant neoplasms in patients with osteosarcoma treated with adjuvant and neoadjuvant chemotherapy: Report of 2 cases [J].
Longhi, A ;
Gamberi, G ;
Bacci, G .
JOURNAL OF CHEMOTHERAPY, 2000, 12 (03) :261-262
[18]   GERM LINE P53 MUTATIONS IN A FAMILIAL SYNDROME OF BREAST-CANCER, SARCOMAS, AND OTHER NEOPLASMS [J].
MALKIN, D ;
LI, FP ;
STRONG, LC ;
FRAUMENI, JF ;
NELSON, CE ;
KIM, DH ;
KASSEL, J ;
GRYKA, MA ;
BISCHOFF, FZ ;
TAINSKY, MA ;
FRIEND, SH .
SCIENCE, 1990, 250 (4985) :1233-1238
[19]   GERMLINE MUTATIONS OF THE P53 TUMOR-SUPPRESSOR GENE IN CHILDREN WITH OSTEOSARCOMA [J].
MCINTYRE, JF ;
SMITHSORENSEN, B ;
FRIEND, SH ;
KASSELL, J ;
BORRESEN, AL ;
YAN, YX ;
RUSSO, C ;
SATO, J ;
BARBIER, N ;
MISER, J ;
MALKIN, D ;
GEBHARDT, MC .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (05) :925-930
[20]  
MEADOWS AT, 1980, CANCER-AM CANCER SOC, V46, P2603, DOI 10.1002/1097-0142(19801215)46:12<2603::AID-CNCR2820461212>3.0.CO